Nucleoside reverse transcriptase inhibitors (NRTIs)

Last updated: November 01, 2022

Nucleoside reverse transcriptase inhibitors (NRTIs)

PANCE REVIEW

PANCE REVIEW

Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Syncope: Clinical
Cardiomyopathies: Clinical
Sympathomimetics: Direct agonists
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Alpha blockers
Sympatholytics: Alpha-2 agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Class I antiarrhythmics: Sodium channel blockers
Class III antiarrhythmics: Potassium channel blockers
Lipid-lowering medications: Statins
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Positive inotropic medications
Immunodeficiencies: Clinical
Glucocorticoids
Laxatives and cathartics
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
HIV and AIDS: Pathology review
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Environmental and chemical toxicities: Pathology review
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Dementia and delirium: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Antihistamines for allergies
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Cholinomimetics: Indirect agonists (anticholinesterases)
Adrenergic antagonists: Presynaptic
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Advanced cardiac life support (ACLS): Clinical
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Pericardial disease: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Multiple sclerosis
Multiple endocrine neoplasia
Congenital adrenal hyperplasia: Clinical

Flashcards

Nucleoside reverse transcriptase inhibitors (NRTIs)

0 of 18 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 3 complete

USMLE® Step 2 style questions USMLE

0 of 6 complete

A 32-year-old woman, gravida 1, para 0, at 38-weeks gestation, presents to labor and delivery triage after several hours of contractions. Currently, they are timed about four minutes apart. She does not have fluid leakage, but she noted a small amount of blood on her underwear just before coming into the hospital. The patient was diagnosed with HIV in the first trimester of pregnancy. The patient has been inconsistent with her combination antiretroviral therapy, and her most recent viral load is 15,000 copies/mL. Temperature is 98.9°F (37.1°C), pulse is 98/min, respirations are 16/min, and blood pressure is 132/84 mm Hg. Pelvic examination in triage reveals a cervix that is three centimeters dilated with a small amount of blood near the introitus. The amniotic fluid sac is tense and palpable. Fetal heart rate tracing is a category I. Which of the following is the best next step in managing this patient?  

Transcript

Watch video only

Reverse transcriptase inhibitors are an important part of HAART, or highly active antiretroviral therapy, which is the combination of medications used in the treatment of AIDS.

AIDS is caused by a RNA containing retrovirus called human immunodeficiency virus, or HIV.

The “retro” part of retrovirus isn’t referring to its style, but refers to it needing to use an enzyme called reverse transcriptase to transcribe a piece of “proviral” DNA from its RNA.

As the name suggests, reverse transcriptase inhibitors go and inhibit this enzyme, and prevent HIV replication.

Based on their structure, they can be classified into nucleoside reverse transcriptase inhibitors, or NRTIs; and non-nucleoside reverse transcriptase inhibitors, or NNRTIs.

NRTIs resemble nucleosides, which are tiny molecules which when attached to a phosphate group give rise to nucleotides, which are building blocks of nucleic acids like DNA and RNA.

HIV is a single-stranded, positive-sense, enveloped RNA retrovirus that targets cells in the immune system that have a molecule called CD4 on their membrane.

These include macrophages, dendritic cells, and especially CD4+ T-helper cells.

Normally, the CD4 molecule helps these cells attach to and communicate with other immune cells, which is particularly important when the cells are launching attacks against foreign pathogens.

HIV attaches to the CD4 molecule via a protein called gp120 found on its envelope.

Now, inside its envelope, HIV contains a nucleocapsid which is a capsule containing a single-stranded RNA and some viral enzymes, like reverse transcriptase and integrase.

As HIV bind to the receptors, the viral envelope fuses with the cell membrane of the immune cell, releasing the contents of the nucleocapsid into the helpless host cell’s cytoplasm.

Once it’s inside the CD4+ cell, reverse transcriptase gets to work immediately.

It uses the single stranded viral RNA as a template, and uses the nucleotides present in the cytoplasm of the CD4+ cell to transcribe a complementary double-stranded “proviral” DNA.

Proviral just means that it’s ready to be integrated into the host’s DNA, so it enters the T-helper cell’s nucleus and pops itself into the cell’s DNA, ready to be transcribed into new viruses, pretty sneaky, huh?

Well here’s the actual sneaky part—when the immune cells become activated, they start transcribing and translating proteins needed for the immune response.

Ironically, this means that whenever the immune cell is exposed to something that causes it to start up an immune response, like any infection, the immune cell ends up inadvertently transcribing and translating new HIV viruses, which bud off from the cell membrane to infect more cells. Very sneaky indeed!

Over time, more and more immune cells are infected, and the immune system begins to fail which is called immunodeficiency, and this increases the risk of infections and tumors that a healthy immune system would usually be able to fend off.

These complications are referred to as AIDS, or acquired immunodeficiency syndrome.

NRTIs are structural analogues of nucleosides.

So, when an NRTI molecule enters the cell, it gets phosphorylated, or a phosphate group is added, and it will resemble a nucleotide.

This fake nucleotide molecule now competes with the natural nucleotide in the infected cell for the attention of reverse transcriptase.

If it’s picked and inserted into the proviral DNA, it will screw up HIV’s entire plan.

Think of DNA like a written instruction for synthesizing proteins, and the nucleotides are the letters.

The NRTI molecule are like random foreign letters that disrupts the instruction so viral proteins can’t be made.

Also, additional nucleotides can not be added to the NRTI molecules inserted into the proDNA so this stops its synthesis.

So instead of the proviral DNA, what we end up with are a bunch of incomplete instructions full of gibberish.

This stops new viruses from being created and keeps other CD4+ cells from getting infected.

Key Takeaways

Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of antiviral drugs used to manage HIV infection, which work by inhibiting HIV's reverse transcriptase enzyme. This enzyme prevents the multiplication of the virus and slows down the progression of the disease. Medications in this class include zidovudine, stavudine, lamivudine, didanosine, and tenofovir. Common side effects may include gastrointestinal disturbances like nausea, vomiting, abdominal pain, insomnia, and headache.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "A Review of the Toxicity of HIV Medications" Journal of Medical Toxicology (2013)
  5. "Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus" PLOS ONE (2016)